Key Takeaways
- Retatrutide is a triple GIP/GLP-1/glucagon receptor co-agonist; mazdutide is a dual GLP-1/glucagon receptor co-agonist. The GIP receptor component is retatrutide's defining mechanistic advantage.
- In the Jastreboff et al. 2023 phase 2 trial (n=338), retatrutide 12 mg weekly produced approximately 17.5% mean body weight reduction at 24 weeks, the largest reported at that timepoint for any injectable obesity drug at the time of publication.
- Mazdutide phase 2 data from Innovent Biologics in Chinese adults with obesity showed weight reductions in the range of roughly 9 to 11% over 24 weeks at studied doses, with no published phase 3 data in non-Asian populations.
- Neither compound is FDA approved as of mid-2026. Retatrutide is in phase 3 (TRIUMPH program). Mazdutide has not filed with the FDA.
- No head-to-head randomized trial between mazdutide and retatrutide exists. All comparisons on this page are cross-trial estimates and should be interpreted with caution.
What Is the Short Answer on Mazdutide vs Retatrutide?
Retatrutide carries an additional GIP receptor agonism that mazdutide lacks, and phase 2 data show numerically larger weight reductions. Mazdutide is a dual GLP-1/glucagon agonist with a solid phase 2 signal but a narrower receptor footprint and a development program centered on Chinese populations. Neither is approved anywhere as of mid-2026.
Table of Contents
- What receptors do mazdutide and retatrutide actually hit?
- What does the clinical evidence show for each?
- Evidence ledger: grading every major claim
- Honest head-to-head comparison table
- Does glucagon receptor agonism help or hurt?
- What most pages get wrong about these two compounds
- Side effect profiles: what the trials actually reported
- Operational and label literacy: reading a COA, sourcing reality
- Frequently asked questions
- Sources
What Receptors Do Mazdutide and Retatrutide Actually Hit?
Mazdutide (IBI362, also called OXM3) is a synthetic long-acting analogue of oxyntomodulin, the naturally occurring gut peptide that activates both GLP-1R and GCGR. Its dual agonism is designed to combine the appetite-suppressing and insulinotropic effects of GLP-1R activation with the energy expenditure and lipolytic effects of glucagon receptor activation. Oxyntomodulin itself has a very short plasma half-life, making it impractical therapeutically. Mazdutide adds fatty acid acylation and other structural modifications to extend its half-life to support once-weekly dosing.
Check your GLP-1 eligibility
Use our free BMI Calculator to see if you may qualify for provider-reviewed GLP-1 therapy.
Try the BMI Calculator →Retatrutide (LY3437943) is an acylated triagonist peptide developed by Eli Lilly. It activates GIP receptor (GIPR), GLP-1 receptor (GLP-1R), and glucagon receptor (GCGR) simultaneously. GIP receptor agonism is the differentiating addition. GIPR activation augments insulin secretion in a glucose-dependent manner and, based on animal and mechanistic data, may potentiate the appetite-suppressing effects of GLP-1R activation rather than opposing them, which was once a prevailing concern in the field.
| Feature | Mazdutide | Retatrutide |
|---|---|---|
| Receptor targets | GLP-1R, GCGR | GIPR, GLP-1R, GCGR |
| Compound class | Dual agonist (incretin/glucagon) | Triple agonist (incretin/incretin/glucagon) |
| Natural analogue basis | Oxyntomodulin | Novel synthetic design |
| Dosing interval (phase 2) | Once weekly | Once weekly |
| Developer | Innovent Biologics | Eli Lilly |
| Development stage (mid-2026) | Phase 2/3 in China; no FDA filing | Phase 3 globally (TRIUMPH program) |
What Does the Clinical Evidence Show for Each?
Retatrutide: The key published human data come from Jastreboff et al. (2023) in the New England Journal of Medicine. This was a phase 2, double-blind, randomized, placebo-controlled trial in 338 adults with obesity (BMI 30 or above) or overweight with at least one weight-related comorbidity. Participants received subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg once weekly, or placebo, over 24 weeks with an optional extension. At 24 weeks, the 12 mg group achieved a mean body weight reduction of approximately 17.5%. At 48 weeks in a subset analysis, the 12 mg group reached approximately 24% mean weight reduction. These are the published figures from that trial. The trial also showed dose-dependent HbA1c reductions in participants with type 2 diabetes.
Mazdutide: Phase 2 data from Innovent Biologics have been presented at scientific conferences and published in journals including The Lancet Diabetes and Endocrinology. A phase 2 randomized trial in Chinese adults with overweight or obesity tested mazdutide at multiple dose levels (doses in the range of 3 mg to 9 mg once weekly were studied). Weight reductions in the range of roughly 9 to 11% were observed over approximately 24 weeks at the higher tested doses. A separate phase 2 trial in Chinese adults with type 2 diabetes showed glycemic benefits alongside weight loss. Enrollment has been in Chinese populations; no published phase 2 or 3 data in predominantly non-Asian populations are available.
Evidence Ledger: Grading Every Major Claim
| Claim | Best Evidence Type | Effect Direction | Confidence |
|---|---|---|---|
| Retatrutide produces substantial weight loss at 12 mg weekly | Phase 2 human RCT (Jastreboff 2023, NEJM, n=338) | Positive, large effect size | Moderate (phase 2 only) |
| Mazdutide produces meaningful weight loss in Chinese adults with obesity | Phase 2 human RCT (Innovent, published in Lancet Diabetes Endocrinol) | Positive, moderate effect size | Moderate (phase 2, single ethnic population) |
| Retatrutide is superior to mazdutide for weight loss | Cross-trial comparison only, no head-to-head | Numerically favors retatrutide | Very Low |
| GLP-1R agonism suppresses appetite via hypothalamic pathways | Multiple human RCTs and mechanistic studies across the class | Positive, well-established | High (class effect) |
| GCGR agonism increases hepatic energy expenditure | Animal studies, human mechanistic studies; isolated GCGR clinical data limited | Positive in animal/mechanistic data | Low to Moderate for isolated human effect |
| GIPR agonism augments rather than undermines GLP-1 effects | Mechanistic studies, tirzepatide phase 3 outcomes, retatrutide phase 2 | Positive (additive or synergistic) | Moderate |
| Neither compound causes net hyperglycemia in clinical use | Phase 2 human RCTs for both | Neutral to beneficial for glycemia | Moderate |
| GI side effects (nausea, vomiting) are common during dose escalation | Phase 2 RCTs for both compounds, consistent with GLP-1 class data | Adverse, mild to moderate, dose-dependent | High (class effect confirmed in both trials) |
| Mazdutide data generalizes to non-Asian populations | No published non-Asian trial data | Unknown | Very Low |
Honest Head-to-Head Comparison Table
| Parameter | Mazdutide | Retatrutide | Winner or Verdict |
|---|---|---|---|
| Receptor targets | GLP-1R, GCGR | GIPR, GLP-1R, GCGR | Retatrutide (broader mechanistic coverage) |
| Best published weight loss (phase 2) | ~9-11% over ~24 wks | ~17.5% at 24 wks (12 mg) | Retatrutide numerically, cross-trial caveat applies |
| Phase 3 data available | No | Ongoing (TRIUMPH) | Retatrutide (more advanced) |
| Global population data | Chinese population primarily | Global trial enrollment | Retatrutide |
| Glycemic benefit in T2D | Yes, phase 2 data | Yes, phase 2 data | Tie (both show HbA1c improvement) |
| GI side effect burden | Moderate, consistent with GLP-1 class | Moderate, consistent with GLP-1 class | Tie (similar class profile) |
| Regulatory approval (mid-2026) | None | None | Tie (both unapproved) |
| Compounded/research access | Limited outside China | Growing research compound market | Retatrutide (more accessible) |
| Long-term cardiovascular outcome data | None published | None published | Tie (both lacking) |
| Cost and commercial pathway | Unclear outside China | Eli Lilly commercial infrastructure | Retatrutide (stronger commercial path) |
Does Glucagon Receptor Agonism Help or Hurt?
This is the chemistry question commodity pages skip. Both compounds activate GCGR, so understanding it matters for both.
Glucagon is classically taught as a glucose-raising hormone: it activates glycogenolysis and gluconeogenesis in the liver, which raises blood glucose. This creates an obvious theoretical concern when adding GCGR agonism to an anti-obesity drug. The counterargument, supported by mechanistic data and both compounds' trial results, is that GCGR activation in the context of simultaneous GLP-1R agonism does not produce net hyperglycemia. GLP-1R activation raises insulin in a glucose-dependent manner, which offsets the glucagon-mediated glucose rise.
Beyond glycemia, GCGR activation increases hepatic fatty acid oxidation, raises basal metabolic rate (documented in animal studies and smaller human mechanistic experiments), and may reduce hepatic lipid accumulation. Animal model data for oxyntomodulin analogues consistently show that the GCGR component adds meaningfully to weight loss beyond what GLP-1R agonism alone achieves. Whether this translates proportionally to humans at clinical doses is not yet established with precision. The key honest caveat: in current multi-agonist trials, the GCGR contribution cannot be isolated from GLP-1R or GIPR effects because no arm tests GCGR alone alongside the combination.
What Most Pages Get Wrong About These Two Compounds
1. Presenting mazdutide phase 2 data as if they apply globally. Mazdutide's published trials enrolled Chinese adults. Body composition, metabolic phenotype, gut microbiome, and response to incretin-based therapies have documented differences between Asian and non-Asian populations. The 9 to 11% weight reduction figure is a real finding in its study population. Whether the same dose would produce the same result in a European or North American population is genuinely unknown.
2. Treating cross-trial weight loss numbers as head-to-head evidence. The 17.5% retatrutide figure and the 9 to 11% mazdutide figure come from different trials, run by different companies, in different countries, with different inclusion criteria, different baseline BMI distributions, and different background standard-of-care. Stating that "retatrutide causes twice the weight loss of mazdutide" is not supported by the data.
3. Ignoring the GIP controversy history. For years, GIP was considered a potential negative contributor to obesity because GIPR-knockout mice showed some protection from diet-induced obesity. The success of tirzepatide (dual GIPR/GLP-1R agonist) in phase 3, producing larger weight loss than semaglutide in the SURMOUNT-1 trial (Jastreboff et al. 2022, NEJM, n=2539), resolved much of this controversy in favor of GIP agonism being additive or synergistic with GLP-1R. Retatrutide adds GCGR on top of this. Mazdutide skips GIPR entirely. This is the central pharmacological bet each drug makes.
4. Glossing over cardiovascular outcome data gaps. Approved GLP-1 agonists (semaglutide, liraglutide) have positive cardiovascular outcome trial data. Neither mazdutide nor retatrutide has completed a cardiovascular outcomes trial. For any patient with established cardiovascular disease, this matters clinically and should be stated plainly.
Side Effect Profiles: What the Trials Actually Reported
For retatrutide, the Jastreboff 2023 phase 2 trial reported that nausea, vomiting, diarrhea, and constipation were the most common treatment-emergent adverse events. These were predominantly mild to moderate in severity. They occurred most frequently during the dose-escalation period. The trial used a slow titration schedule to manage tolerability. Discontinuation due to adverse events was higher in the higher-dose groups than in placebo, but exact discontinuation rates at each dose are reported in the published trial supplementary data. No new safety signals beyond the known GLP-1 class profile were identified in phase 2, though phase 2 sample sizes are not powered to detect rare events.
For mazdutide, published phase 2 data similarly showed GI adverse events as the dominant side effect category, consistent with the GLP-1R agonist class. Hypoglycemia risk was low in non-diabetic participants, as expected given the glucose-dependent mechanism of GLP-1R-mediated insulin release.
A theoretical concern with GCGR agonism is elevated liver enzymes or changes in hepatic lipid metabolism. Published trial data for both mazdutide and retatrutide have not flagged clinically significant hepatotoxicity signals in phase 2, but neither trial was sized or designed to detect hepatic events as a primary endpoint.
Operational and Label Literacy: Reading a COA, Sourcing Reality
Because neither compound is FDA-approved, any material available outside of a formal clinical trial setting exists as a research compound. This section explains what that means practically.
Certificate of Analysis (COA) minimum requirements: A credible COA for either peptide should state purity by HPLC (high-performance liquid chromatography) as a percentage, ideally above 98% for research-grade material. It should include molecular weight confirmation by mass spectrometry, identity confirmation matching the published amino acid sequence, and testing for endotoxins (bacterial lipopolysaccharide contamination) if the material is intended for any injectable use. A COA that lists only one analytical method, provides no endotoxin data, or comes from a third-party lab with no traceable accreditation is insufficient.
Stability and storage: Both compounds are peptides that degrade under certain conditions. Lyophilized (freeze-dried) powder is substantially more stable than reconstituted solution. Once reconstituted in bacteriostatic water, peptide solutions should be kept refrigerated at 2 to 8 degrees Celsius and used within the timeframe recommended by the manufacturer based on their stability testing. Repeated freeze-thaw cycles of reconstituted solution degrade peptide bonds. UV light accelerates oxidation of susceptible amino acid residues (methionine, tryptophan). Amber vials are not decorative. The practical gotcha: if a product arrives as a pre-mixed solution rather than lyophilized powder, the effective shelf life before degradation is shorter and harder to track.
Reconstitution math: For a hypothetical 5 mg lyophilized vial of retatrutide (dose range in phase 2 extended to 12 mg weekly): adding 1 mL of bacteriostatic water yields 5 mg/mL. A 4 mg dose would require 0.8 mL of that solution drawn into an insulin syringe. Always double-check: volume in mL equals desired dose in mg divided by concentration in mg/mL. Simple arithmetic errors at this step create significant dosing inaccuracies.
Sourcing reality: Research compound markets are unregulated with respect to actual peptide purity and identity. Published audits of peptide research compounds have found a meaningful proportion of samples that do not match their labeled concentration or contain detectable impurities. This is not specific to mazdutide or retatrutide but applies to all peptides in this market. Requesting a third-party COA and cross-checking the mass spectrum against the published molecular weight of the specific compound is the minimum quality check a researcher should perform.
Frequently Asked Questions
What is the main mechanistic difference between mazdutide and retatrutide?
Mazdutide is a dual GLP-1/glucagon receptor co-agonist. Retatrutide is a triple GIP/GLP-1/glucagon receptor co-agonist. The addition of GIP agonism in retatrutide is the key structural difference and is believed to contribute to its larger observed weight loss in phase 2 data.
Which compound showed greater weight loss in clinical trials?
In phase 2 trials, retatrutide at the highest tested dose (12 mg weekly) produced mean body weight reductions of approximately 17.5% at 24 weeks and around 24% at 48 weeks. Mazdutide phase 2 data showed reductions in the range of 9 to 11% over comparable periods at tested doses, though direct head-to-head data do not exist.
Is mazdutide or retatrutide FDA approved?
Neither mazdutide nor retatrutide is FDA approved as of mid-2026. Retatrutide (Eli Lilly) is in phase 3 trials. Mazdutide (Innovent Biologics) has primarily been studied in Chinese populations and has not filed for FDA approval.
What receptors does retatrutide target?
Retatrutide is a co-agonist at three receptors: glucagon-like peptide-1 receptor (GLP-1R), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon receptor (GCGR). This triple agonism is why it is sometimes called a triagonist.
What receptors does mazdutide target?
Mazdutide (also known as IBI362 or OXM3) targets two receptors: GLP-1R and GCGR (glucagon receptor). It is a synthetic analogue of oxyntomodulin, a naturally occurring gut peptide that acts at both receptors.
What are the main side effects of retatrutide?
In the Jastreboff et al. 2023 phase 2 trial, nausea, vomiting, diarrhea, and constipation were the most common side effects, consistent with GLP-1 class effects. These were predominantly mild to moderate and occurred most frequently during dose escalation.
How does mazdutide compare to semaglutide?
Mazdutide adds glucagon receptor agonism on top of GLP-1R action, which theoretically increases energy expenditure beyond what a pure GLP-1 agonist like semaglutide achieves. Phase 2 data from Innovent suggest modestly greater weight reduction than historical semaglutide 1 mg comparators, but no direct randomized comparison exists.
Can retatrutide cause hyperglycemia due to glucagon agonism?
Glucagon receptor agonism can raise blood glucose in isolation, but in the context of GLP-1R co-agonism, the insulinotropic effect counterbalances this. Clinical data from phase 2 retatrutide trials did not show net hyperglycemia; in fact, HbA1c reductions were observed in participants with type 2 diabetes.
What is the half-life of retatrutide and mazdutide?
Retatrutide has a half-life that supports once-weekly subcutaneous dosing, similar to semaglutide. Mazdutide in its phase 2 trials was also dosed once weekly. Exact published half-life values from peer-reviewed pharmacokinetic data are not yet widely available for either compound outside of trial protocols.
Is retatrutide better than tirzepatide?
Phase 2 retatrutide data suggest numerically larger weight loss than tirzepatide phase 3 data at comparable timepoints, but these are cross-trial comparisons with different populations and designs, not head-to-head evidence. Phase 3 retatrutide data are needed before any superiority claim is credible.
Where is retatrutide in clinical development?
As of mid-2026, retatrutide is in phase 3 clinical trials for obesity and type 2 diabetes under Eli Lilly. Phase 3 programs include the TRIUMPH series. No approval has been granted in any major regulatory jurisdiction.
What does the glucagon receptor agonism component actually do for weight loss?
Glucagon receptor activation increases hepatic energy expenditure, promotes fatty acid oxidation, and may suppress appetite via central nervous system pathways. In animal models it reliably increases metabolic rate. In human trials, distinguishing its isolated contribution from GLP-1 or GIP effects is not yet possible because all three are delivered simultaneously.
Sources
- Jastreboff AM, Kaplan LM, Frías JP, et al. Triple-Hormone-Receptor Agonist Retatrutide for Obesity: A Phase 2 Trial. N Engl J Med. 2023;389(6):514-526. PMID 37366315.
- Jastreboff AM, Aronne LJ, Ahmad NN, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. PMID 35658024.
- Cui Y, Li X, Lu W, et al. Mazdutide (IBI362) in Chinese adults with overweight or obesity: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Diabetes Endocrinol. Published 2023. [Innovent Biologics phase 2 trial data.]
- Day JW, Ottaway N, Patterson JT, et al. A new glucagon and GLP-1 co-agonist eliminates obesity in rodents. Nat Chem Biol. 2009;5(10):749-757. PMID 19648929. [Foundational dual GLP-1/glucagon agonist mechanism paper.]
- Samms RJ, Coghlan MP, Sloop KW. How May GIP Enhance the Therapeutic Efficacy of GLP-1? Trends Endocrinol Metab. 2020;31(6):410-421. PMID 32386999.
- Baggio LL, Drucker DJ. Biology of Incretins: GLP-1 and GIP. Gastroenterology. 2007;132(6):2131-2157. PMID 17498508.
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. Cell Metab. 2018;27(4):740-756. PMID 29617641.
- ClinicalTrials.gov. Retatrutide TRIUMPH Phase 3 Program. NCT listings for LY3437943. Accessed May 2026.
- Innovent Biologics. IBI362/OXM3 (Mazdutide) Phase 2/3 Clinical Trial Registry Data. ClinicalTrials.gov. Accessed May 2026.
- US FDA. Compounded Drug Products That Are Essentially Copies of a Commercially Available Drug Product Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Guidance for Industry. 2018.